This prospective, observational study will assess the effectiveness and safety of Avastin (bevacizumab) as 1st line therapy in elderly patients with advanced non-squamous non-small cell lung cancer in clinical practice. Therapy with Avastin and standard chemotherapy will be administered according to the treating physician. Data will be collected for approximately 4 years.

Inclusion Criteria:

• Adult patients, >= 65 years of age
• Diagnosis of advanced non squamous Non-Small Cell Lung Carcinoma (nsNSCLC, stage IIIB or IV) for whom the physician has decided to initiate a treatment with Avastin combined with chemotherapy as 1st line therapy
• Having received oral and written information about the study, and having signed a written consent form

Exclusion Criteria:

• Participation in a cancer clinical trial with an investigational medicinal product other than this study
• Patient previously treated with Avastin
• Patient under supervision or guardianship

Patients aged over 65 years with non-squamous non-small cell lung cancer